LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Pfizer

Затворен

СекторЗдравеопазване

22.82 1.06

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.45

Максимум

22.82

Ключови измерители

By Trading Economics

Приходи

2.6B

3B

Продажби

-4B

14B

P/E

Средно за сектора

16.732

56.602

EPS

0.92

Дивидентна доходност

7.72

Марж на печалбата

21.633

Служители

81,000

EBITDA

2B

4.5B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+26.88% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

7.72%

2.45%

Следващи печалби

29.07.2025 г.

Следваща дата на дивидент

13.06.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-14B

131B

Предишно отваряне

21.76

Предишно затваряне

22.82

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.05.2025 г., 18:41 ч. UTC

Значими двигатели на пазара

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29.04.2025 г., 11:24 ч. UTC

Печалби

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

15.05.2025 г., 15:20 ч. UTC

Топ новини

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12.05.2025 г., 22:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12.05.2025 г., 18:45 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12.05.2025 г., 17:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12.05.2025 г., 09:02 ч. UTC

Горещи акции

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7.05.2025 г., 17:01 ч. UTC

Топ новини

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7.05.2025 г., 09:30 ч. UTC

Топ новини

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5.05.2025 г., 15:13 ч. UTC

Пазарно говорене
Печалби

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1.05.2025 г., 14:07 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1.05.2025 г., 11:58 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1.05.2025 г., 11:06 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1.05.2025 г., 10:48 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29.04.2025 г., 19:47 ч. UTC

Печалби

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29.04.2025 г., 18:11 ч. UTC

Печалби

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29.04.2025 г., 15:22 ч. UTC

Печалби

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29.04.2025 г., 12:03 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29.04.2025 г., 11:46 ч. UTC

Печалби

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29.04.2025 г., 11:42 ч. UTC

Печалби

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29.04.2025 г., 11:12 ч. UTC

Печалби

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29.04.2025 г., 10:52 ч. UTC

Печалби

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29.04.2025 г., 10:51 ч. UTC

Печалби

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29.04.2025 г., 10:50 ч. UTC

Печалби

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29.04.2025 г., 10:47 ч. UTC

Печалби

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29.04.2025 г., 10:47 ч. UTC

Печалби

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29.04.2025 г., 10:46 ч. UTC

Печалби

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29.04.2025 г., 10:45 ч. UTC

Печалби

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

29.04.2025 г., 10:45 ч. UTC

Печалби

Pfizer 1Q EPS 52c >PFE

29.04.2025 г., 10:45 ч. UTC

Печалби

Pfizer 1Q Adj EPS 92c >PFE

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

26.88% нагоре

12-месечна прогноза

Среден 27.94 USD  26.88%

Висок 32 USD

Нисък 24 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

5

Купи

13

Задържане

0

Продай

Техническа оценка

By Trading Central

22.855 / 23.85Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.